Notch Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Toronto ON Canada

Primary Industry

Biotechnology

About

Founded in 2018 and based in Toronto, Canada, Notch Therapeutics, Inc. operates as a biotechnology company that develops immunotherapy drugs. The company was founded by Sunnybrook Research Institute and the University of Toronto. In February 2021, Notch Therapeutics, Inc. received USD 85 million in series A funding from Allogene Therapeutics, Inc., Lumira Ventures, CCRM Enterprises Holdings Ltd., EcoR1 Capital, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. The company develops a pipeline of cellular immunotherapies intended to generate T cells and other immune cells from the clonal stem. The company produces stem cell-derived, gene-edited immune cell therapies and the differentiation of induced pluripotent stem cells without the use of any animal components. The company's revenue is generated from developing immunotherapy drugs in the field of cancer. Notch Therapeutics, Inc. plans to continue the development of Notch's portfolio. The company also plans to expand its team.

Current Investors

Allogene Therapeutics, Inc., Casdin Capital, EcoR1 Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.notchtx.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.